CHAGE 201 IPF
Alternative Names: CHAGE 201-IPFLatest Information Update: 31 Mar 2025
At a glance
- Originator CHA Bio & Diostech
- Class Gene therapies; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Idiopathic pulmonary fibrosis
Most Recent Events
- 12 Mar 2025 Phase-I/II clinical trials in Idiopathic pulmonary fibrosis (Parenteral) before March 2025 (CHA Bio & Diostech pipeline, March 2025)
- 12 Mar 2025 Preclinical trials in Idiopathic pulmonary fibrosis in South Korea (Parenteral) before March 2025